Ascendis Pharma (ASND) Prices 4.225M ADS Offering at $14/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Ascendis Pharma (ASND) Announces Proposed $500M ADS Offering
July 6, 2020 1:00 PM EDTAscendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it has commenced an underwritten public offering of $500,000,000 of American Depositary Shares (ADSs), each of which represents one ordinary share... More
Ascendis Pharma (ASND) Receives Positive Opinion from Paediatric Committee of the European Medicines Agency on Agreement of Paediatric Investigation Plan
July 6, 2020 9:25 AM EDTAscendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it received a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) on its agreement with the proposed Paediatric Investigation Plan (PIP) for TransCon hGH (lonapegsomatropin), an investigational long-acting once-weekly prodrug of somatropin (human growth hormone or hGH) in development for treatment of growth hormone deficiency (GHD). The positive opinion is based on the non-clinical safety program, as well as data from the three phase 3 clinical... More
